Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
228
datasets available to search
ShareScore release 0.9.0
Dataset results
228 results for “model therapy”
Associated code and data for "Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization (doi: 10.3389/fcell.2021.74635)"
<p>This deposit contains the data, code, and analysis to reproduce the results in the manuscript - Lai X, Keller C, Santos-Rosales G, Schaft N, Dörrie J, Vera J. Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization. Frontiers in Cell and Developmental Biolology. 2022; 9:746359; <a href="https://www.researchgate.net/publication/358461035_Multi-Level_Computational_Modeling_of_Anti-Cancer_Dendritic_Cell_Vaccination_Utilized_to_Select_Molecular_Targets_for_Therapy_Optimization">doi:10.3389/fcell.2021.746359</a>.</p> <p>If you have used the code for your research, please cite the original publication. Thank you very much.</p> <p> </p>
Development of a machine learning model to predict non- durable response to anti-TNF therapy in Crohn's disease using transcriptome imputed from genotypes
<p>This is the expression value predicted using PrediXcan version 7 to find a gene feature that can distinguish between patients with and without effect on infliximab.</p> <p>Among the various tissue models provided by PrediXcan v7, three models were selected and used: whole blood, Colon transverse, and terminal ileum of small intestine, and the predicted gene counts of each model were 6,294, 5,612 and 3,107.</p> <p>For each of the three models, predicted gene expression values and phenotype information per sample were submitted.</p>
Figure 9. A model that helps the diagnosis prediction-Modern Tools in Patient-Centred Speech Therapy for Romanian Language
<p>We have already implemented many modules of Logo-DM, such as: data cleaning module, data transformation module, feature extraction module, data clustering module and a classification module for diagnosis prediction. Figure 9 shows the model achieved using a decision tree built on complex examination data that aims to predict the patient’s diagnosis. Currently, we are testing the built models on new cases in order to estimate their quality.</p>
A comparative study of the effectivity of MSC-based, NP-based and combined therapies in an experimental model of NaIO3-induced retinal degeneration
<div><strong>Background</strong></div> <div>Mesenchymal stem cells (MSCs) are currently tested as one of the promising options for the therapy of retinal diseases, due to their immunomodulatory and neuroprotective abilities. However, there are several limitations associated with this type of treatment. Therefore, combinations of MSCs with other therapeutic agents are being considered. One of such approaches is represented by the application of MSCs with nanoparticles (NPs), which are widely used in medicine for their antimicrobial and immunomodulatory properties. Nevertheless, there is a possibility of negative effects of NPs on MSCs.</div> <div><strong>Methods</strong></div> <div>In this study, we tested the <em>in vitro</em> and <em>in vivo</em> effect of silver (Ag) NPs on the properties of MSCs in an experimental mouse model of chronic retinal degeneration induced by sodium iodate.</div> <div><strong>Results</strong></div> <div>The results showed that simultaneous intravitreal administration of MSCs with AgNPs had no effect on the survival of MSCs in the eye, but a less effective regulation of Iba-1 (activated microglia/macrophages) and interleukin-1β expression in the retinal tissue compared to MSCs or AgNP only treated groups was observed. However, all treated groups had decreased expression of the gene for galectin-3 compared to the untreated control. In addition, MSCs applied alone or in combination with AgNPs and sorted from the degenerated retina on day 7 after application had increased expression of genes for specific retinal markers, and for transforming growth factor-β and insulin-like growth factor-1 compared to untreated naïve MSCs. On the contrary, the increased expression of the gene for glial cell-derived growth factor was observed only in the MSCs combined with AgNPs. However, the application of MSCs with AgNPs triggered increased expression for the IL-6 gene in the CD45 cells separated from the retina.</div> <div><strong>Conclusion</strong></div> <div>Overall, the results show that the application of MSCs or AgNPs has an immunomodulatory effect in chronic retinal degeneration, but the combined application of MSCs and AgNPs could decrease the effects of a single therapy.</div>
'CellTrajectory' for cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies
Open the record for dataset details and reuse information.
'Biosim' for cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies
Open the record for dataset details and reuse information.
Dataset related to article "Intracranial Sonodynamic Therapy With 5-Aminolevulinic Acid and Sodium Fluorescein Safety Study in a Porcine Model"
<p>pigs treatments</p>
Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy
<p>Chronic granulomatous disease (CGD) is a rare inherited disorder due to loss-of-function mutations in genes encoding the NADPH oxidase subunits. Hematopoietic stem and progenitor cell (HSPC) gene therapy (GT) using regulated lentiviral vectors (LVs) has emerged as a promising therapeutic option for CGD patients. We performed non-clinical Good Laboratory Practice (GLP) and laboratory-grade studies to assess the safety and genotoxicity of LV targeting myeloid specific Gp91phox expression in X-linked chronic granulomatous disease (XCGD) mice. We found persistence of gene-corrected cells for up to 1 year, restoration of Gp91phox expression and NADPH oxidase activity in XCGD phagocytes, and reduced tissue inflammation after LV-mediated HSPC GT.<br> Although most of the mice showed no hematological or biochemical toxicity, a small subset of XCGD GT mice developed<br> T cell lymphoblastic lymphoma (2.94%) and myeloid leukemia (5.88%). No hematological malignancies were identified in C57BL/6 mice transplanted with transduced XCGD HSPCs. Integration pattern analysis revealed an oligoclonal composition with rare dominant clones harboring vector insertions near oncogenes in mice with tumors. Collectively, our data support the long-term efficacy of LV-mediated HSPC GT in XCGD mice and provide a safety warning because the chronic inflammatory XCGD background may contribute to oncogenesis.</p>
Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalised therapy
<div> <div> <div> <p>Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, a disease with dismal overall survival. Advances in treatment are hindered by a lack of preclinical models. Here we show how a personalised organotypic 'avatar' created from resected tissue, allows spatial and temporal reporting on a complete in situ tumour microenvironment, and mirrors clinical responses. Our perfusion culture method extends tumour slice viability, maintaining stable tumour content, metabolism, stromal composition, and immune cell populations for 12 days. Using multiplexed immunofluorescence and spatial transcriptomics, we identify immune neighbourhoods and potential for immunotherapy. We employed avatars to assess the impact of a pre-clinically validated metabolic therapy and show recovery of stromal and immune phenotypes and tumour re-differentiation. To determine clinical relevance, we monitored avatar response to gemcitabine treatment and identified a patient avatar-predicable response from clinical follow-up. Thus, avatars provide valuable information for the syngeneic testing of novel therapeutics and a truly personalised therapeutic assessment platform for patients.</p> </div> </div> </div>
Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa
<p><span>Retinitis pigmentosa is an inherited photoreceptor degeneration that begins with rod loss followed by cone loss. This cell loss greatly diminishes vision, with most patients becoming legally blind. Gene therapies are being developed, but it is unknown how retinal function depends on the time of intervention. To uncover this dependence, we utilize a mouse model of retinitis pigmentosa capable of artificial genetic rescue. This model enables a benchmark of best-case gene therapy by removing variables that complicate the ability to answer this vital question. Complete genetic rescue was performed at 25%, 50%, and 70% rod loss (early, mid, and late, respectively). Here we show early- and mid-treatment restores retinal function to near wild-type levels, specifically the sensitivity and signal fidelity of retinal ganglion cells, the output neurons of the retina. However, some anatomical defects persist. Late treatment retinas exhibit continued, albeit slowed, loss of sensitivity and signal fidelity among retinal ganglion cells, as well as persistent gliosis. We conclude that gene replacement therapies delivered after 50% rod loss are unlikely to restore visual function to normal. This is critical information for administering gene therapies to rescue vision.</span></p>
Development and Validation of the Client Centered Occupational Therapy Service Model
ClinicalTrials.gov study NCT04465422. IPD Sharing: NO. Countries: 1. Publications: 4.
Investigation of Two Swallowing Therapy Models During Radiation Therapy for Head and Neck Cancer
ClinicalTrials.gov study NCT03832686. IPD Sharing: NO. Countries: 1. Publications: 1.
Large Linguistic Model for Clinical Reaoning of Physical Therapy Students
ClinicalTrials.gov study NCT06809634. IPD Sharing: NO. Countries: 1. Publications: 2.
Improving Medication Therapy Through a Digital Interdisciplinary Medicine Therapy Optimisation Model
ClinicalTrials.gov study NCT05629936. IPD Sharing: NO. Countries: 1. Publications: 1.
Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalised therapy
Open the record for dataset details and reuse information.
Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa
Open the record for dataset details and reuse information.
Patient-specific models of dyssynchronous heart failure for assessment of regional work in patients undergoing cardiac resynchronization therapy
Open the record for dataset details and reuse information.
Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation
ClinicalTrials.gov study NCT02795650. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Efficacy of Manual Therapy Based on the Fascial Distortion Model in Individuals With Temporomandibular Disorder
ClinicalTrials.gov study NCT06134310. IPD Sharing: NO. Countries: 1. Publications: 0.
Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)
ClinicalTrials.gov study NCT06009315. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.